Nick Pizzie Sells 3,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Axsome Therapeutics Stock Performance

Shares of AXSM stock opened at $131.15 on Friday. The business’s fifty day simple moving average is $97.84 and its 200-day simple moving average is $93.32. The company has a market cap of $6.36 billion, a PE ratio of -20.08 and a beta of 1.05. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $134.18.

Analysts Set New Price Targets

AXSM has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a report on Monday, February 10th. Bank of America boosted their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $190.00 price target on shares of Axsome Therapeutics in a report on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Friday, January 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $147.13.

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the business. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics during the fourth quarter worth $52,000. R Squared Ltd purchased a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $64,000. Aquatic Capital Management LLC purchased a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $76,000. KBC Group NV grew its holdings in shares of Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after buying an additional 385 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Axsome Therapeutics by 22.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after buying an additional 318 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.